Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Many pharmacies refusing to give fourth shots to immune-compromised patients

The US Centers for Disease Control and Prevention plans to send a clear message to pharmacies on a conference call this week: Stop turning away immune-compromised people when they come seeking fourth doses of Covid-19 vaccines.

Although fourth doses are not currently recommended for the vast majority of Americans, the CDC has urged millions of people with compromised immune systems to get them.

But many immune-compromised people tell CNN that pharmacies and hospitals have refused to give them fourth doses, leaving those most vulnerable to the virus without the protection the CDC wants them to have.

“A lot of pharmacies are just not understanding. They hear ‘fourth shot,’ and it just freaks them out,” said Elizabeth Nunn, who is immune-compromised and was turned away for a fourth shot by three pharmacies near her home north of New York City.

Source: CNN

https://www.cnn.com/2022/01/26/health/fourth-shots-immune-compromised/index.html

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!